These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21093172)

  • 21. The value of Day 1 imaging following LDR prostate brachytherapy.
    Nobes JP; Laing R; Langley S
    Radiother Oncol; 2008 Feb; 86(2):288-9; author reply 289-90. PubMed ID: 17963906
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose verification with Monte Carlo technique for prostate brachytherapy implants with (125)I sources.
    Zhang H; Baker C; McKinsey R; Meigooni A
    Med Dosim; 2005; 30(2):85-91. PubMed ID: 15922174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the use of a surrogate urethra an option in prostate high-dose-rate brachytherapy?
    Nilsson J; Kälkner KM; Berg L; Levitt S; Holmberg C; Nilsson S; Lundell M
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):36-40. PubMed ID: 17980507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
    Vicini FA; Kestin LL; Martinez AA
    Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations.
    Fuller DB; Naitoh J; Lee C; Hardy S; Jin H
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1588-97. PubMed ID: 18374232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
    Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
    Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
    Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methodology for biologically-based treatment planning for combined low-dose-rate (permanent implant) and high-dose-rate (fractionated) treatment of prostate cancer.
    Zaider M; Zelefsky MJ; Cohen GN; Chui CS; Yorke ED; Ben-Porat L; Happersett L
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):702-13. PubMed ID: 15708248
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Feasibility and toxicity of a single fraction high-dose-rate brachytherapy followed by a course of EBRT for localized prostate cancer: a retrospective study. The Polyclinique Courlancy experience].
    Mallet F; Wdowczyk D; Bruna A; Villena P; Herard A; Amory JP; Joffroy P; Pangrazzi T
    Cancer Radiother; 2010 Jan; 14(1):11-8. PubMed ID: 20005765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo dosimetry of high-dose-rate interstitial brachytherapy in the pelvic region: use of a radiophotoluminescence glass dosimeter for measurement of 1004 points in 66 patients with pelvic malignancy.
    Nose T; Koizumi M; Yoshida K; Nishiyama K; Sasaki J; Ohnishi T; Kozuka T; Gomi K; Oguchi M; Sumida I; Takahashi Y; Ito A; Yamashita T
    Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):626-33. PubMed ID: 18164870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
    Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
    Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
    Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
    Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of inverse planning simulated annealing and geometrical optimization for prostate high-dose-rate brachytherapy.
    Hsu IC; Lessard E; Weinberg V; Pouliot J
    Brachytherapy; 2004; 3(3):147-52. PubMed ID: 15533807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. On the use of a single-fiber multipoint plastic scintillation detector for 192Ir high-dose-rate brachytherapy.
    Therriault-Proulx F; Beddar S; Beaulieu L
    Med Phys; 2013 Jun; 40(6):062101. PubMed ID: 23718599
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of radiation dose to the urethra on brachytherapy-related dysuria.
    Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Lief JH; Reed DJ
    Brachytherapy; 2005; 4(1):45-50. PubMed ID: 15737906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate high-dose-rate brachytherapy as salvage treatment of local failure after previous external or permanent seed irradiation for prostate cancer.
    Tharp M; Hardacre M; Bennett R; Jones WT; Stuhldreher D; Vaught J
    Brachytherapy; 2008; 7(3):231-6. PubMed ID: 18579446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
    J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
    Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
    J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Technology Insight: Combined external-beam radiation therapy and brachytherapy in the management of prostate cancer.
    Hurwitz MD
    Nat Clin Pract Oncol; 2008 Nov; 5(11):668-76. PubMed ID: 18825143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.